November 21st 2023
Joshua Richter, MD, discusses how bispecific antibodies fit into the current treatment armamentarium for patients with multiple myeloma, highlighting his presentation from the 41st Annual CFS®.
August 8th 2023
After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
August 1st 2023
Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.
Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.
July 25th 2023
A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.
Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.
July 18th 2023
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.
Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.
July 11th 2023
Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.
A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.
July 4th 2023
Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.
Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.
June 27th 2023
Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.
Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.
June 20th 2023
Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.
Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.
June 25th 2021
Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Factors to consider when choosing the optimal treatment approach after the first relapse of multiple myeloma.
June 18th 2021
James Hoffman, MD, and Joshua Richter, MD, discuss the IKEMA study, the appropriate selection of therapy, and the differences between various options.